secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2026-07-08T13:03:46+00:00
Accession:  0001570562-26-000079
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus licenses Profhilo for U.S. skin-quality market; no upfront payment
-------------------------------------------------------------------------

- Exclusive license to develop and commercialize Profhilo in the U.S. for aesthetics and dermatology.
- No upfront or milestone payments; economics via transfer-price model supporting target gross margins.
- Evolus responsible for U.S. development and FDA approval; initial term 15 years from first approval.
- Profhilo has 4.8M+ treatments globally since 2015; market leader in European injectable skin quality.
- Agreement does not affect 2026 revenue/opex/operating profit outlook or 2028 targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056226000079/0001570562-26-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056226000079/eols-20260707.htm
  HTML page:      https://secwatch.observer/filing/0001570562-26-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer